Pd15-12 Health Care Spending in High Resource Prostate Cancer Patients: What Contributes Most to High Prostate Cancer Health Care Costs?
Year: 2019
Type: article
Study design: Observational Study
Abstract: date were identified from 01 April 2014 to 31 March 2017.Patients had continuous VHA enrollment for !12 months pre-and post-index date and were followed until death or disenrollment.Kaplan-Meier analysis was conducted to estimate OS and Cox proportional hazards regression models examined the impact of treatment on survival.Patients initiating abiraterone acetate were 1:1 propensity score matched (PSM) with those initiating enzalutamide.All-cause and PCrelated resource use and costs per-patient-per-month (PPPM) were compared between the matched cohorts during the 12 months postindex date.RESULTS: This study included 1,945 abiraterone acetate and 1,229 enzalutamide mCRPC patients with mean ages of 73 and 74 years respectively.After a median follow-up of 18 months and 19 months, enzalutamide and abiraterone acetate patients had a median survival time of 30 months and 26 months, respectively.In the Cox analysis, enzalutamide patients had better survival compared to abiraterone acetate patients (HR[0.87;95%CI 0.78-0.96).After PSM, there were 1,160 patients left in both cohorts.Compared to abiraterone acetate patients, enzalutamide patients had fewer mean all-cause outpatient visits PPPM (2.51 vs 2.86; p<.0001) and fewer mean PC-related outpatient visits PPPM (0.86 vs 1.03; p<.0001).Enzalutamide patients also had lower mean all-cause outpatient costs PPPM ($2,588 vs $3,115; p<.0001) and mean total costs PPPM ($8,085 vs $9,092; p[.0002); lower mean PC-related outpatient costs PPPM ($1,356 vs $1,775; p<.0001) and mean total costs PPPM ($6,321 vs $7,280; p<.0001) than abiraterone acetate patients.CONCLUSIONS: Chemotherapy-naive mCRPC patients treated with enzalutamide had better survival, significantly lower resource use and healthcare costs than patients treated with abiraterone acetate.
Source: The Journal of Urology
Language: English
Subfield: Economics and Econometrics
Domain: Social Sciences
Open Access status: bronze
Funder: Pfizer
OpenAlex ID: W2942471446